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Abstract Recent development in stem cell isolation
methods and expansion under laboratory conditions create
an opportunity to use those aforementioned cells in tissue
engineering and regenerative medicine. Particular attention
is drawn towards mesenchymal stem cells (MSCs) being
multipotent progenitors exhibiting several unique charac-
teristics, including high proliferation potential, self-
renewal abilities and multilineage differentiation into cells
of mesodermal and non-mesodermal origin. High abun-
dance of MSCs found in adipose tissue makes it a very
attractive source of adult stem cells for further use in
regenerative medicine applications. Despite immunomod-
ulating properties of adipose-derived stem cells (ASCs) and
a secretion of a wide variety of paracrine factors that
facilitate tissue regeneration, effectiveness of stem cell
therapy was not supported by the results of clinical trials.
Lack of a single, universal stem cell marker, patient-to-
patient variability, heterogeneity of ASC population com-
bined with multiple widely different protocols of cell
isolation and expansion hinder the ability to precisely
identify and analyze biological properties of stem cells.
The above issues contribute to conflicting data reported in
literature. We will review the comprehensive information
concerning characteristic features of ASCs. We will also
review the regenerative potential and clinical application
based on various clinical trials.
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Introduction
In the past, adipose tissue was considered only a passive
energy storage. Since the mid-80’s of the last century,
when its participation in the metabolism of sex hormones
was confirmed, adipose tissue has become an important
endocrine organ that controls metabolism, immunity and
satiety (Seo et al. 2004). The real breakthrough was made
in 2001 when a new source of adult stem cells, called
adipose-derived stem cells (ASCs), isolated from adipose
tissue, was described for the first time (Zuk et al. 2001).
Adipose tissue is considered a type of connective tissue
exhibiting morphological, functional and regulatory
heterogeneity (Furstenberg et al. 2010). The interaction
between adipose tissue and other tissues or organs is cer-
tainly bidirectional (Skowron´ska et al. 2005). It affects the
functioning of most physiological systems, including the
immune, reproductive, and hematopoietic system (Baptista
et al. 2015). Development, amount and distribution of
adipose tissue in the body is a result of the nervous system,
hormones and transcription factors effects (Baptista et al.
2015; Furstenberg et al. 2010). In terms of macroscopic
features five types of adipose tissue [bone marrow (BM),
brown and white mammary glands and mechanical adipose
tissue] can be distinguished, each of them with a different,
distinct biological function (Gimble et al. 2007).
Since the identification of stem cells in the BM over
40 years ago, they have become a standard in the field of
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tissue engineering and regenerative medicine (Friedenstein
et al. 1968; Lindroos et al. 2011). Bone marrow aspiration,
however, is a painful and expensive procedure that requires
general anesthesia. Moreover, the yield of isolated cells is
usually low (Lindroos et al. 2011). Multipotent mesenchy-
mal stem cells (MSCs) are present in a number of postnatal
organs and connective tissues. MSCs, with similar charac-
teristics to BM-derived MSCs, have been successfully
isolated from different tissue sources including periosteum,
synovium, skeletal muscle, skin, peripheral blood and
umbilical cord (Kuroda et al. 2011). Although the stem cell
populations derived from these sources are valuable, com-
mon problems include low harvested cells yield and limited
amount of harvested tissues. Adipose tissue seems to be a
great alternative source of acquiring stem cells, especially
with the increased incidence of obesity which makes the
tissue abundant and readily accessible. It can be collected in
large quantities with low possibility of donor site morbidity,
during a much safer and less time consuming liposuction
procedure (Uzbas et al. 2015). Approximately 400,000
liposuction surgeries are performed in the US each year and
these procedures yield from 100 ml to[3 l of lipoaspirate
tissue, which is routinely discarded (Bunnell et al. 2008).
Furthermore, the high content of ASCs in adipose tissue,
excludes the need of long-term in vitro culture, what reduces
the risk of chromosomal abnormalities. Such properties
make the ASCs an attractive tool in clinical application for
therapeutic purposes (Baptista et al. 2015; Nakagami et al.
2006; Uzbas et al. 2015).
Collection of Adipose Tissue: Liposuction
The method of adipose tissue collection, for the purpose of
stem cell isolation, raises a number of controversies.
Researchers are eager to use adipose tissue, which is
considered a waste product of abdominoplasty, cosmetic
surgery or liposuction (Gimble et al. 2010). Liposuction is
currently the most common aesthetic surgery widely used
around the world. The first step is the infiltration of the fat
(of the area to be aspirated) using a large amount of the
lidocaine, epinephrine, sodium bicarbonate, and saline
composition (to reduce the risk of blood loss). Infiltration
methods include the super-wet technique (1 ml infiltration
per 1 ml aspiration) and the tumescent technique (2–3
infiltration cm3 per 1 cm3 aspiration) (Heymans et al.
2006). Subsequently the separated fat tissue with the
injected solution is aspirated via a cannula of different
diameter (Sood et al. 2011; Vivek et al. 2014).
Several liposuction techniques such as standard lipo-
suction, suction assisted liposuction, internal ultrasound
assisted liposuction, external ultrasound assisted liposuc-
tion, laser assisted liposuction, power-assisted liposuction,
and vibroliposuction are currently in clinical use (Heymans
et al. 2006). A brief description of selected methods is
shown in Table 1.
Depending on the technique and location, the liposuc-
tion procedures are performed under local, peripheral or
general anesthesia (Sood et al. 2011). Liposuction is
regarded as a generally safe and well-tolerated procedure
with minimal post-operative discomfort. The study per-
formed by the American Society for Dermatologic
showed no recorded deaths at nearly 70,000 liposuction
procedures carried out between 1994 and 2000, and
serious adverse events were very rare at the rate of 0.68
per 1000 cases (Fraser et al. 2006). Compared to the BM
aspiration, liposuction procedures are much less invasive,
cheaper, and even a small amount of adipose tissue
(100–200 ml) is enough to isolate a suitable number of
stem cells under local anesthesia (Orbay et al. 2012).
Other methods such as syringe-based harvest may give
higher yields of adipocytes but are not as widely used as
Table 1 Characteristic of selected liposuction methods
Technique Characteristic
Standard and suction assisted
liposuction





Emulsifying the fat tissue with a vibrating at high ultrasound probe, emulsion removal by the small diameter
cannula
Power-assisted liposuction The separation of adipose tissue by the set forward and backward motion cannula, divided fat tissue is sucked
into the cannula, considered as the safest and most effective method
Laser-assisted liposuction Adipocytes separation and liquidation of tissue via a cannula emitting the laser ray, gentle aspiration of the
liquid fat tissue through the cannula
Modified according to Heymans et al. (2006)
There are several liposuction techniques currently available to remove fatty tissue from different sites on the human body. In the tumescent
techniques, that reduce post operative bruising, swelling and pain in comparison to older more traditional methods, subcutaneous fat is injected
with a large volume of diluted anesthetic and capillary constrictor before liposuction is performed
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vacuum liposuction (Eto et al. 2009). Surgical fat excision
being more invasive may be used less often but the ASC’s
yield is over 50 % higher compared to liposuction (Fraster
et al. 2007).
The Stromal Vascular Fraction
Isolation procedures of fat tissue components are conver-
gent in the standard methods, based on enzymatic
digestion. Those methods are designed to separate the two
easily recognizable fractions, mature adipocytes and the
stromal vascular fraction (SVF). After collagenase diges-
tion, mature adipocytes with a high fat content are
separated as a floating layer. All cells, which remain after
the removal of mature adipocytes constitute the SVF
(Peinado et al. 2012). The composition of the SVF varies
among individual research groups. It is commonly known,
however, that it includes preadipocytes, endothelial cells,
pericytes, fibroblasts, ASCs and hematopoietic stem cells
(Peinado et al. 2012; Zuk et al. 2001). The SVF also
contains erythrocytes, lymphocytes T, B cells, macro-
phages, and mast cells (Peinado et al. 2012). Stem cells and
progenitor cells determine about 3 % of all cell populations
(Tsuji et al. 2014).
Cytometric analysis performed by Yoshimura et al.
(2006) identified the following cell populations in SVF:
ASCs (CD31-/CD34?/CD45-/CD90?/CD105-/CD146-),
endothelial progenitor cells (CD31?/CD34?/CD45-/
CD90?/CD105low/CD146??), pericytes (CD31-/CD34-/
CD45-/CD90?/CD105-/CD146?) and blood cells
(CD45?), suggesting also the presence of fibroblasts, vas-
cular smooth muscle cells and preadipocytes. Taking into
account the surface markers expression, the heterogeneous
isolates of SVF can be represented as follows: 11 % CD2?
cells, 18 % CD11a? cells, 29 % CD14? cells, 49 %
CD31? cells, 57 % CD45? cells and 60 % CD90? cells
(Brzoska et al. 2005). Another research group presented
composition of SVF slightly different: 11 % CD14? cells,
*2 % CD31? cells, *7 % CD34? cells, *9 % CD45?
cells, *29 % CD90? cells and *47 % CD146? cells
(Astori et al. 2007). It was also observed that 85 % SVF
cells, which underwent adhesion, exhibit the CD31-/
CD34?/CD45-/CD105? phenotype (Varma et al. 2007).
The expression of hematopoietic markers such as CD11,
CD14, CD34, and CD45 dissipate is lost during the SVF
in vitro passaging. On the other hand, the expression level
of some markers, e.g. CD29, CD73, CD90, and CD166
increases in higher passages (Tsuji et al. 2014). That is why
passaging is considered a selecting factor when it comes to
cell populations with more homogenous cell surface
markers compared to SVF.
Isolation of ASCs from Adipose Tissue
For the first time the isolation of rat mature adipocytes and
adipose tissue progenitor cells was described by Rodbell
(1964). The protocol was based on the disintegration of
adipose tissue into small fragments followed by enzymatic
digestion with collagenase type I in 37 C and the fol-
lowing centrifugation to separate distinct cell fractions.
The obtained supernatant was composed of mature adipo-
cytes and the pellet fraction consisted of the SVF
components, in which the progenitor cells of adipocytes
were presumably present. This procedure was effectively
modified and used with small volumes of fat tissue by
many research groups like (Cawthorn et al. 2012; Tsuji
et al. 2014).
Katz et al. (1999), Zuk et al. (2001) and Uzbas et al.
(2015) demonstrated that SVF isolated from human
lipoaspirates contains multipotent cells. To isolate these
cells enzymatic digestion was used followed by their
adhesion to the bottom of culture flasks. Enzymatic
digestion and adhesion properties of ASCs still comprise
the basis of their isolation (Lindroos et al. 2011). One of
the novel methods of ASCs isolation is the use of antibody-
coated immunomagnetic beads, which are able not only to
‘‘catch’’ ASCs cells, but also other subpopulations of stem
cells found in adipose tissue (Rada et al. 2009).
Katz et al. (2001) developed a device known as the ‘‘bag
within a bag’’, which enables the aspiration of pre-injected
saline and tissue to the inner bag. This system is extremely
useful for contamination removal and helps to automate the
isolation protocol to some degree (Katz et al. 2001). The
same group developed a rotary, temperature control device
to digest even 1 l of tissue at a time (Katz et al. 1999). In
addition to the cell isolation it also separates the extracel-
lular matrix of adipose tissue, which may be used as a
potent biomaterial.
Isolation of ASCs on a large scale is possible with the
use of commercially available systems, such as Celu-
tionTM (Cytori Therapeutics, San Diego, USA) (Lin et al.
2008b; Tissue Genesis Incorporated 2009). These systems
allow for fast and safe isolation of large numbers of
autologous stem cells, ready for immediate application.
CelutionTM Cytori system was used in a clinical trial of
stress urinary incontinence treatment, which showed
promising results (Yamamoto et al. 2010).
The most important advantage of ASCs is their abun-
dance. From 1 g of adipose tissue an average of
0.5–2.0 9 106 SVF cells can be isolated, which gives
1–10 % of stem cells yield (Bear et al. 2013) for compar-
ison MSCs constitute 0.001–0.01 % of BM (Pittenger et al.
1999). Some sources claim that the number of isolated cells
can be even greater, and amount to about 2–6 9 106 cells
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from 1 ml of tissue (Kim and Jeong 2014). The number of
ASCs isolated from 1 g of fat tissue ranges between
0.5 9 104 and 2 9 105 (Baer and Geiger 2012). These
differences are caused by donor characteristics, such as
gender, age, ethnicity, BMI, disease history and also the
type of fat tissue (yellow/brown), location (subcutaneous/
visceral fat) and the tissue collection method or culture
conditions (Baer and Geiger 2012; Olkowska-Truchanow-
icz 2008).
Impact of Culture on Senescence and Genetic
Stability of ASCs
The protocol of ASCs culture varies between laboratories
and currently there is not a single, unified method avail-
able. Most commonly it is a monolayer culture in standard
medium supplemented with 10 % fetal bovine serum
(Mizuno et al. 2012). The growth factors can affect the
undifferentiated state of ASCs. Under in vitro conditions
stem cells phenotype may be affected by growth medium
used for ASC culture, specific supplements added to basic
growth medium and environment conditions at which cells
are grown. Even the use of serum-containing standard
medium may induce their differentiation. Under in vitro
conditions ASC’s phenotype may be affected by a wide
variety of factors, ranging from growth medium choice and
the type of supplementation used (serum, platelet lysate,
growth factors, corticoids, antioxidants) to environment
and culture conditions such as culture perfusion, mechan-
ical load, confluence level or substance stiffness. ASC’s are
also especially sensitive to oxygen levels, if possible
complete hypoxia condition would be best for their cul-
turing (Baer and Geiger 2012).
In comparison to BM-MSCs, ASCs have a higher pro-
liferative capability. The population doubling time, in the
logarithmic growth phase, ranges 40–120 h and depends on
age of the donor, type and location of the adipose tissue,
method of collection, culture conditions, cells density and
medium composition used by teams of De Ugarte et al.
(2003), Izadpanah et al. (2006), Mitchell et al. (2006) and
Zuk et al. (2001). ASCs show telomerase activity, and
although it is lower than in the tumor cell lines, it testifies
the ability of ASCs for self-renewal and proliferation (Jeon
et al. 2011). These cells maintain telomere length during
long-term culture, but whether telomerase activity is sus-
tained at a constant level or decreases with successive
passages is still open to debate (Izadpanah et al. 2006; Jeon
et al. 2011). Sachs et al. (2012) documented the lack of
telomerase expression in ASCs. Moreover, telomeres were
gradually shortening with age, indicating a telomere-based
senescence mechanism (Sachs et al. 2012).
Taking into account that stem cells previously cultured
in vitro can be safely transplanted, there is a great need to
further investigate their abilities to maintain chromosome
stability in non-physiological conditions. ASCs exhibit
higher genetic stability in long-term culture compared to
BM-MSCs (Dahl et al. 2008; Neri et al. 2013). However,
research carried out by at least one research group has
shown that karyotype irregularities occur with a frequency
of[30 %. The occurrence of neoplastic transformation of
ASCs maintained in culture for more than four months was
also observed (Rubio et al. 2005). The relevance of a clear
tendency towards increased aneuploidy with in vitro cul-
ture is still being debated (Sensebe et al. 2012). It appears
crucial to perform a detailed analysis of the genome prior
to any cell-based treatment. Special caution in conducting
and selecting the ASCs culture is needed, as it can be
crucial for maintaining their diplioidal karyotype.
Phenotype and Niche of ASCs
All previous attempts to determine the phenotype of ASCs
and identification of one unique marker for these cells were
unsuccessful. It is assumed that these cells express fol-
lowing markers: CD13, CD29, CD44, CD49b, CD90,
CD105 and do not express the hematopoietic markers, such
as CD14, CD31, CD45 and CD144 as described by Zuk
(2013). Additional studies, evaluating the ASCs differen-
tiation, suggested that these cells have a specific expression
of CD34 marker and the absence of CD31/CD45 (Varma
et al. 2007; Yoshimura et al. 2006). The expression profile
of cell surface markers of human ASCs is presented in
Table 2.
Stem cell niche is a microenvironment, which controls
the properties of stem cells and gene expression. It consists
of signaling molecules, interactions between cells them-
selves, stem cells and the extracellular matrix (Fuchs et al.
2004). The niche of ASCs in adipose tissue has not been
clarified. However, a number of recent studies indicate that
it can be identified in adipose tissue vascularization process
like shown by (Leto Barone et al. 2013; Lin et al. 2008a;
Zimmerlin et al. 2010). Zimmerlin et al. (2010) identified
the ASCs on outer adventitia of blood vessels. Expression
of CD146 and 3G5 and the pericytes markers suggests that
these cells can be identified as pericytes located in the
vasculature of adipose tissue (Crisan et al. 2008; Zannet-
tino et al. 2008). This hypothesis may enhance the fact that
processes like adipogenesis and angiogenesis are closely
related, adipose tissue is a highly vascularized tissue, and
pericytes exhibit similar multipotency as stem cells
(Crandall et al. 1997; Feng et al. 2010; Zannettino et al.
2008).
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Expression of CD146 by ASCs, however, raises a lot of
doubt. It also impedes the possibility of confirmation that
pericytes and ASCs are the same cells (Sensebe et al. 2012).
Moreover, Maumus et al. (2011) in immunohistological anal-
ysis presented that native ASCs exhibit specific morphological
characteristics. In addition, native ASCs can be found in the
adipose tissue matrix. An argument against the classification of
ASCs as pericytes militates is the fact that they do not express
markers characteristic to pericytes in vivo, such as NG2,
CD140b or alpha smooth muscle actin (expression occurs
during in vitro culture) (Casteilla et al. 2011). Rodeheffer et al.
(2008) identified another subpopulation of early adipocyte
progenitor cells in a mice model (Lin-, CD29?, CD34?, Sca-
1?, CD24?), which is located in white adipose tissue.
Table 2 The expression profile of ASCs surface markers
Protein Name CD
Positive expression




Intercellular adhesion molecule-1 CD54 (ICAM-1)
Receptor molecules Hyaluronan receptor CD44
Transferrin receptor CD71
a-Platelet-derived growth factor CD140a
Enzymes Neutral endopeptidase CD10 (CALLA)
Aminopeptidase CD13
Ecto-50-nucleotidase CD73





Cytoskeletal proteins Vimentin –
Regulatory proteins of the complement system Complement decay-accelerating factor CD55
MAC-inhibitory protein CD59
Histocompatibility proteins HLA-A, -B, -C (class I) –
Negative expression
Adhesion molecules Vascular cell adhesion protein 1 CD106 (VCAM)
Lymphocyte function-associated antigen 1 CD11a
Mac-1a CD11b
Integrin a-X CD11c
Platelet endothelial cell adhesion molecule CD31
VE-cadherin CD144
Receptor molecules LPS receptor CD14
Enzymes Tyrosine phosphatase CD45
Controversy expression
Adhesion molecules Endoglin CD105
MUC-18 CD146
Activated leukocyte cell adhesion molecule CD166 (ALCAM)
Receptor molecules Platelet derived growth factor receptor CD140b
Muscle proteins Smooth muscle actin –
Histocompatibility proteins HLA-DR –
Modified according to Zuk (2013)
Adipose-derives stem cells exhibit specific cell surface expression pattern. Despite intensive search single unique marker have not been
identified. ASCs are mainly identified on the basis of their high expression of CD105, CD90, CD44, CD73 in the absence of CD34, CD14 and
CD45
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The cause of contradictions concerning the profile of
ASCs is not known. It may have emerged as a result of
various isolation and cultivation methods used or various
location-dependent origins of ASCs (Casteilla et al. 2011).
The presence of several stem cell populations within SVF
of adipose tissue, such as endothelial precursor cell popu-
lation, population of perivascular ASCs or pericytes
population can also be the reason of that problem (Tsuji
et al. 2014; Zeve et al. 2009).
Mechanisms Responsible for Regenerative
Properties of ASCs
Several mechanisms can be responsible for the regenera-
tive potential of ASCs. Some studies suggest that ASCs act
via differentiation towards a specific cell type, thereby
replacing defective cell populations in vivo. However,
studies conducted on animal models, which allow for
tracking ASCs in vivo do not confirm the aforementioned
hypothesis (Gimble et al. 2012). With an exception of the
‘‘classic’’ mesenchymal phenotype (differentiation into
adipocytes, osteoblasts, chondrocytes) none of the studies
confirm the total and functional differentiation of mes-
enchymal-like cells. The phenotype of differentiated cells
is mostly confirmed only by the expression of specific
markers (Casteilla et al. 2011).
Some studies suggest that MSCs differentiation may
lead to ‘‘intermediate two-phenotypic cells’’, which show
co-expression of specific cells and stromal markers without
obtaining actual functionality (Rose et al. 2008). In such
case, MSCs undergoing a specific differentiation would
only express markers of ‘‘truly differentiated cells’’, with-
out demonstrating all of their functionality. Another
unresolved problem is whether cells transdifferentiation is
a result of their fusion which is considered to be the main
mechanism for the formation of new functional cells (Ut-
sunomiya et al. 2011). In a study conducted by Aurich et al.
(2009), there was no detected fusion of the implanted
ASCs, differentiated towards hepatocytes, with hepatocytes
of the host.
Another proposed mechanism of ASCs activity is the
modulation stem cell niche of the host by stimulating the
recruitment of endogenous stem cells to the damaged area
and their commitment in the proper lineage. ASCs may be
also a source of antioxidants, free radical scavengers and
chaperone/heat shock proteins at the site of tissue damage.
As a result of their actions, toxic substances are separated,
removed and the surviving cells can restore their function
(Friedenstein et al. 1968). Currently, many researchers
believe that ASCs promote cell regeneration of tissues and
organs, primarily through the release of cytokines and
growth factors (Gimble et al. 2012).
Paracrine and Immunomodulatory Properties
of ASCs
ASCs promote tissue regeneration by secreting cytokines
and growth factors that stimulate restoration of normal
tissue function or reduce its damage. Molecules secreted by
ASCs have a positive effect on the central nervous system,
immune system, heart, muscles and even the general
vitality of cells (Salgado et al. 2010).
ASCs cell cytokine profile (Table 3) comprises, inter
alia, vascular endothelial growth factor (VEGF), granu-
locyte/macrophage colony-stimulating factor, cell-derived
stromal factor 1-alpha, hepatocyte growth factor (HGF),
transforming growth factor b, and fibroblast growth factor
2, which explains their impressive angiogenic properties
and ability to induce tissue neovascularization (Gir et al.
2012; Sterodimas et al. 2010). Among the secreted anti-
apoptotic factors it is worth to mention about insulin-like
growth factor-1 (IGF-1), which, as was shown, may pro-
tect the cardiomyocytes against apoptosis (Sadat et al.
2007).
Table 3 ASCs cytokine profile
Function Secreted protein
Immunomodulation TGF-b, HGF, PGE2, IL-6
Vascularization VEGF, HGF, TGF-b2, FGF-2, bFGF, GM-CSF
CUN regeneration BDNF, NGF, GDNF, IGF-1
Hematopoiesis suport HGF, GM-CSF, IL-6,7,8,11, TNF-a
Other Adiponectin, angiotensin, cathepsin D, retinol binding protein, CXCL12
Modified according to Salgado et al. (2010)
Adipose-derived stem cells secrete several cytokines and growth factors that modulate immune response and facilitate regeneration of damaged
tissues. These soluble mediators exhibit positive effect on central nervous system, heart, muscles and even the general vitality of cells
GM-CSF granulocyte/macrophage colony-stimulating factor, TGF-b transforming growth factor b, FGF-2 fibroblast growth factor 2, BDNF
brain derived neurotrophic factor, GDNF glial derived neurotrophic factor, NGF nerve growth factor
448 Arch. Immunol. Ther. Exp. (2016) 64:443–454
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ASCs promote the regeneration of central nervous sys-
tem cells and show a neuroprotective activity by secretion
of brain derived neurotrophic factor, glial derived neu-
rotrophic factor, nerve growth factor and IGF (Salgado
et al. 2010). There is also evidence that growth factors,
secreted by ASCs, stimulate the growth of fibroblasts and
keratinocytes (Hong et al. 2013). In response to inflam-
matory stimuli, derived from adipose tissue, expression of
angiogenic factors (VEGF, HGF, IGF-1), and hematopoi-
etic/inflammatory factors (G-CSF, M-CSF, IL-6, TNF-a) in
ASCs is increased (Kilroy et al. 2007).
ASCs are also immunoprivileged due to the lack of
HLA-DR expression and the proliferation inhibition of
activated allogeneic lymphocytes (Aust et al. 2004; Gon-
zalez-Rey et al. 2010; Mitchell et al. 2006). ASCs inhibit
the generation of pro-inflammatory cytokines, stimulate the
production of anti-inflammatory IL-10 cytokine and induce
the formation of antigen-specific regulatory T cells (Gon-
zalez-Rey et al. 2010). The immunosuppressive properties
of ASCs also result from the production of prostaglandin
E2 and 2,3 dioxygenase indole (Gimble et al. 2011). These
cells also protect against organ rejection and prevent from
graft versus host disease after allogeneic stem cell trans-
plantation (Yan˜ez et al. 2006). Immunomodulatory
properties have been confirmed both in vitro and in vivo
(Baer 2014; Le Blanc et al. 2003; Nagaya et al. 2014; Patel
et al. 2008).
Multilineage Differentiation Potential of ASCs
Literature provides abundant evidence concerning the
in vitro multipotency of ASCs. Furthermore, this property
is maintained during long-term culture (Baer and Geiger
2012). It is generally believed that ASCs origin from
mesoderm, therefore, their potential to differentiate
towards adipocytes, chondrocytes, osteoblasts and myo-
cytes should be obvious and was confirmed in many studies
(Mizuno 2009). Induction of ASCs differentiation in vitro
occurs mainly by culturing cells in culture media supple-
mented with specific growth factors (Baer and Geiger
2012). Subsequent studies have expanded the potential of
adipose derived stem cells on the ability to differentiate
into non-mesodermal cells, i.e. ecto- and endodermal
(Mizuno 2009).
ASCs support hematopoiesis and angiogenesis, also
their differentiation potential toward endothelial cells and
their participation in the blood vessels formation is con-
firmed in literature (Sood et al. 2011). Aforementioned
cells cultured in vitro on the matrigel quickly and easily
form a vascular-like structure adopting the endothelium
function (Cao et al. 2005; Sood et al. 2011). Formation of
the functional vascularization by these cells was confirmed
in vivo in a number of models such as: myocardial
infarction, regeneration of epithelium and nerve tissue
(Baptista et al. 2015).
Some reports about the possibility of ASCs differentia-
tion into the insulin-producing b cells, glucagon and
somatostatin appeared in literature (Colazzo et al. 2010).
ASCs were able to differentiate towards hepatocyte-like
cells, expressing albumin and a-fetoprotein, LDL uptake
and urea production (Lindroos et al. 2011). In vivo, hepa-
tocyte-like cells derived from ASCs reconstitute the
function of hepatocytes (Timper et al. 2006).
Findings concerning the ASCs participation in the for-
mation of functional neurons are contradictory. Some
studies confirm their differentiation into neuronal cells,
both morphologically and functionally (Seo et al. 2005).
Many researchers see hope in treatment of nerve injuries
using ASCs thus, confirming their participation in neuronal
regeneration (Mizuno et al. 2012; Khalifian et al. 2015;
Zack-Williams et al. 2015).
However, in most cases, the analysis of ASCs multi-
potency is based, on morphology and surface marker
expression of differentiated cells in vitro (Di Summa et al.
2010). Only a hand full of studies evaluate the differenti-
ation effect in terms of functionality, such as the myocytes
contractility (Johal et al. 2015; Rangappa et al. 2003).
Currently the main focus of researchers regarding the
potential of in vivo transplanted ASCs lies in the context of
tissue engineering and regenerative medicine (Table 4) (Di
Summa et al. 2010).
Clinical Studies with ASCs
In clinical applications, ASCs were used for the first time
in year 2004, when they were implanted together with a
bone fragment, fibrin glue and a biodegradable scaffold to
regenerate a large bone defect in the skull of 7-year-old girl
(Hoekstra 2011). Currently, the quantity of proposals for
the use of these cells in tissue repair and regeneration is
impressive. Number of clinical trials evaluating the effi-
cacy and safety of ASCs in tissue reconstruction and
regeneration increases significantly each year.
According to the clinical trials database (ClinicalTri-
als.gov database 2015) there are 122 studies currently
registered as using adipose derived stem cells. These
studies include treatment of: diabetes, liver cirrhosis, fis-
tulas, cardiovascular disease, limb ischemia, amyotrophic
lateral sclerosis, lipodystrophy, graft versus host disease,
Crohn’s disease, atherosclerosis, soft-tissue augmentation
and bone defects (Table 5) (Lendeckel et al. 2004). As Kim
and Jeong (2014) stated in his review, ACSs are more
liberally used in clinical treatment in Korea and Japan for
plastic surgery and esthetic treatments because of legal
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123
reasons. Most of currently conducted research is at its early
stages (Table 6), and the study population do not not
exceed 100 patients. A large amount of studies contains
only a descriptions of cases rather than randomized trials,
without any control groups. Five studies were terminated
(Table 7), including the cirrhosis treatment due to a lack of
efficacy.
Clinical studies are generally based on the use of the
whole SVF, isolated ASCs (alone or in combination with
biomaterials) or fat tissue itself enriched with ASCs.
Table 4 In vitro and in vivo multipotency of ASCs










Yes Yes Gelatin matrix ? preinduced human
ASCs, subcutaneous, mice lacking
thymus
Fibrin glue ? GFP ? murine visceral
ASCs, subcutaneous, mouse
Osteoblasts/bone 25-Dihydroxyvitamin D3,
glycerophosphate, ascorbic acid, bone
morphogenetic protein-2, valproic acid
Yes Yes PLGA scaffold ? human ASCs induced
toward osteoblasts, skull damage, rats
lackingthymus
PLA scaffold ? rat ASCs induced
toward osteoblasts, palate damage, rats
Chondrocytes/cartilage FGF, TGF-b, dexamethasone, IGH, bone
morphogenetic protein-6, ascorbic
acid, insulin
Yes Yes PLGA scaffold ? induced with TGF-b1
human ASCs, subcutaneous, mice
lacking thymus
Fibrin glue ? rabbit ASCs, cartilage
damage, rabbits
Skeletal myocytes Dexamethasone, horse serum, co-culture
with primary myoblasts or myoblast
cell lines
Yes Yes Preinduced human ASCs ? mouse
model of muscular dystrophy
Cardiomyocytes Interleukin-3, interleukin-6, transferrin,
VEGF, 5-azacytidine
Yes/No Yes ASCs ? injection into the myocardial,
infarction model, rats lacking thymus
Cardiomyoblasts derived from human




Heparin, TGF-b1, bone morphogenetic
protein-4
Yes Yes ASCs co-culture with human bladder
smooth muscle ? injection into the
bladder, mice lacking thymus
Rats ASCs, model of stress urinary
incontinence, rats
Endothelial cells EGF, bFGF, hydrocortisone Yes/no Yes Human ASCs ? model of hindlimb
ischemia, mice
Rats ASCs ? model of ischemia–
reperfusion injury, rats, intravenous
administration
Nerve cells Valproic acid, insulin, hydrocortisone,
EGF, FGF
Yes/no Yes Schwann cells derived from ASCs ? rat
spinal cord injury, rats
ASCs induced toward neurogenesis ? rat
focal brain injury, rats
Hepatocytes HGF, oncostatin, dimethylsulfoxide Yes Yes Human ASCs ? partial hepatectomy,
mice lacking thymus, intravenous
Human ASCs ? CCl4-induced liver
injury, mice lacking thymic
b cells pancreatic islet Nicotinamide, activin-A, exendin-4,
HGF, pentagastrin, glucose
Yes Yes Rats ASCs ? Pdx1 transduction,
streptozotocin-induced diabetes, rats
Modified according to Cawthorn et al. (2012), Hoekstra (2011), Yarak and Okamoto (2010) and Zuk (2013)
Adipose derived stem cells have potential to differentiate into cells of mesodermal and non-mesodermal origin. When maintained under optimal
growth conditions they have been shown to be multipotent, capable of differentiating down the adipogenic, osteogenic and chondrogenic
lineages. Differentiation into other cell types, i.e. cardiomyocytes or endothelial cells was also confirmed
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Studies differ in the ASCs type used, some use autologous
ASCs, other allogenic ones. There is also a significant
difference in density of transplanted cells and the route of
their administration. It is also worth to note that some
studies are based on the immunomodulatory and angio-
genic properties of ASCs. These studies concern the
treatment of autoimmune diseases, ischaemia or diabetic
wounds of lower limbs. Researches based on ASCs dif-
ferentiation, include treatment of degenerative arthritis,
cardiac or spinal injury.
Why the Cell-Based Therapies Can Fail?
The development of tissue engineering, regenerative medicine
and cell based therapies will surely prevent many currently
incurable diseases. However, before achieving an efficient
clinical application it is necessary to overcome many technical
limitations. There are certainly a lot of questions that should be
addressed at preclinical and clinical levels, e.g. spontaneous
differentiation of stem cells into target cells or the problem of
cell migration and homing mechanisms. We have to consider
adipose tissue as an effective regeneration tool, isolation of a
homogenous stem cell fraction is crucial. Recently, a whole
adipose tissue-derived SVF became popular in clinical appli-
cations, especially in one-step surgeries in the field of
orthopedics. However, there is little data concerning a full
characterization of this fraction, which is very heterogeneous.
It contains the mixture of endothelial cells, smooth muscle
cells, fibroblast, pericytes and mast cells. In such therapies we
transplant the whole microenvironment of stem cells rather
than just stem cells alone. Therefore it is not surprising that
grafts with the SVF fraction give promising results. However,




Diabetes and its complications 6
Gastrointestinal and urogenital tract





Eractile dysfunction/urethral structure 4
Ischemia
Angiogenesis/Burger disease/limb ischemia 12
Vascular occlusive disease of the kidney 1
Myocardial infarction 4














Chronic obstructive pulmonary disease/pulmonary
fibrosis
5
Dry macular degeneration/retinal degeneration 2
Pain 2
Acute respiratory distress syndrome 1
Sepsis 1
On the basis of (ClinicalTrials.gov database 2015)
Adipose derived stem cells are currently used in several clinical trials.
Most of them concern gastrointestinal and urogenital tract pathologies
and cartilage and bone degeneration
GvHD graft versus host disease
Table 6 Phase of clinical trials with the use of ASCs









On the basis of (ClinicalTrials.gov database 2015)
Most of ongoing clinical trials evaluating regenerative potential of
adipose-derives stem cells are at early stage of the study. Their main
goal is to assess stem cell therapy safety within small groups of
patients and identify its side effects
Table 7 Status of clinical trials with the use of ASCs





On the basis of (ClinicalTrials.gov database 2015)
Majority of clinical trials evaluating efficacy of stem cell therapy are
at early stage of patient recruitment. Only 20 % were finished. Some
studies were interrupted including cirrhosis treatment due to lack of
efficacy
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we need to understand the mechanism of action before intro-
ducing it to common clinical practice. There is a huge need to
answer which factors give and support the best therapeutic
effect, especially in long-term basis. Further questions arise,
whether the grafted stem cells can maintain their undifferen-
tiated state or do they differentiate. This last issue is very
important in the light of a possibility of undesirable ASCs
differentiation and their interaction with tumor cells. It has
been reported that these cells, in some cases, may favor tumor
growth (Prantl et al. 2010), or quite the opposite, inhibiting the
the proliferation of cancer cells (Cousin et al. 2009). Some
studies, carried out on primary tumor cells, conclude that ASCs
can induce tumor cell growth in the presence of active tumor
cells but not mitoticly inactive ones (Zimmerlin et al. 2011).
Eterno et al. (2014) showed that ASCs may support the pro-
liferation of breast cancer cells through the activation of HGF/
c-Met/beta-catenin axis, which is very important in the light of
increased breast cancer recurrence rates after fat grafts. These
contradictory results generate the need for more detailed
molecular characterization of adipose derived stem cells.
Unfortunately, information relating to undesirable ASCs dif-
ferentiation is very limited. The only described case regards the
appearance of cysts and microcalcifications in 4 of 70 patients
undergoing breast reconstruction using lipoaspiration enriched
by SVF (Yoshimura et al. 2008). This may be due to the fact
that such a phenomenon is rare or has not been fully investi-
gated. Further studies are necessary to elucidate themechanism
of stem cell transformation, which will greatly contribute to
cell fate regulation and inhibition of oncogenesis in different
organs. Summarizing, it is very important to be aware that stem
cell therapies, despite the great hope, also poses weakness and
limitation. We have to isolate and culture immune-specific and
homogenous stem cell populations, improve the efficiency of
differentiation into target cells, establish an optimal stage of
transplantation and improve the post-transplantation migration
and regeneration rate (Bajek et al. 2014; Lim et al. 2011).
Conclusion
Although, there are dozens of clinical studies using ASCs,
there is an apparent lack of reports that unambiguously
confirm the effectiveness of this type of cell therapy. Still,
many important questions remain before effective clinical
applications of ASCs therapies for humans arise. Never-
theless, the clinical use of ASCs is undeniably very
exciting and draws a lot of attention.
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